FDA Approves Schering's Integrilin
Integrilin keeps the platelets in your blood from coagulating (clotting) to prevent unwanted blood clots that can occur with certain heart or blood vessel conditions.
Integrilin is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries)
For the treatment of patients with acute coronary syndrome (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, Integrilin has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction.
Integrilin is used to treat patients with severe chest pain or small heart attacks and for those undergoing certain heart procedures (e.g., balloon angioplasty). Integrilin has been shown to decrease the chance of another heart attack or death.
Integrilin has also been shown to decrease the risk of another heart attack or death and reduce the need for urgent medical care in patients undergoing certain heart procedures.